Company intelligence / Profile preview

Intact

Palo Alto, California, United Statesintactspecialty.com ↗

Ownership: Private
Development stage: Commercial

Overview

Intact Therapeutics is a clinical-stage biopharmaceutical company developing next-generation therapies for gastrointestinal diseases. Its lead product is a rectal thermosensitive gel formulation of mesalamine designed to deliver targeted therapy for mild-to-moderate ulcerative colitis. The company’s proprietary smart gel technology enables site-specific, localized drug release within the digestive tract to improve efficacy and reduce systemic side effects. The company has filed multiple patents related to dosing methods for treating inflammatory bowel conditions but has not yet reported pivotal clinical results.

Therapeutic areas: Gastroenterology
Modalities: Small moleculeThermosensitive gel drug delivery systemDevice
Industry: Biotech

Beyond the preview

Go deeper on Intact.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intact.

Explore the full profile